General Information of the Compound
Compound ID
CP0457842
Compound Name
US10058534, 139
    Show/Hide
Synonyms
(2E)-3-[4-({2-[2-(1,1-difluoroethyl)-4-fluorophenyl]-6-hydroxy-1-benzothiophen-3-yl}oxy)phenyl]prop-2-enoic acid
(E)-3-(4-((2-(2-(1,1-difluoroethyl)-4-fluorophenyl)-6-hydroxybenzo [b]thiophen-3-yl)oxy)phenyl)acrylic acid
(E)-3-(4-((2-(2-(1,1-difluoroethyl)-4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3-yl)oxy)phenyl)acrylic acid
2135600-76-7
BCP29222
BDBM269484
C6V
CS-0042193
EX-A1874
HY-111486
LSZ-102
LSZ102
SCHEMBL17334098
SJXNPGGVGZXKKI-NYYWCZLTSA-N
US10058534, 139
    Show/Hide
Structure
Formula
C25H17F3O4S
Molecular Weight
470.468
Canonical SMILES
CC(F)(F)c1cc(F)ccc1-c1sc2cc(O)ccc2c1Oc1ccc(\C=C\C(O)=O)cc1
    Show/Hide
InChI
InChI=1S/C25H17F3O4S/c1-25(27,28)20-12-15(26)5-9-18(20)24-23(19-10-6-16(29)13-21(19)33-24)32-17-7-2-14(3-8-17)4-11-22(30)31/h2-13,29H,1H3,(H,30,31)/b11-4+
    Show/Hide
InChIKey
SJXNPGGVGZXKKI-NYYWCZLTSA-N
Physicochemical Property
logP
7.4148
Rotatable Bonds
6
Heavy Atom Count
33
Polar Areas
66.76
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
4
Complexity
33

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 118574930
ChEMBL ID
CHEMBL4076124
DrugBank ID
DB15362
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound

Compound
Cell Line
Protein

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT00886, Estrogen receptor
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000083 MCF-7 Homo sapiens (Human)  3
1
IC50 = 0.2 nM
   TI
   LI
   LO
   TS
2
IC50 = 6 nM
   TI
   LI
   LO
   TS
3
IC50 = 8.9 nM
   TI
   LI
   LO
   TS
Clinical Information about the Compound
Drug 1 ( LSZ102 )
Drug Name LSZ102
Company Novartis Oncology East Hanover, NJ
Indication
Breast cancer
Phase 1